Market Overview

Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

Share:

Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

PR Newswire

MALVERN, Pa., Aug. 8, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announces today that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.

A live and archived webcast of the Wedbush presentation will be available on the Events and Presentations page of the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signalling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

G-RLM

Contacts:

Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating Officer
Outside US:  +44 (0) 20 3727 1000
US:  +1 212 600 1902

Argot Partners
Stephanie Marks / Claudia Styslinger
+1 212 600 1902

FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000

Cision View original content:http://www.prnewswire.com/news-releases/realm-therapeutics-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-300693471.html

SOURCE Realm Therapeutics

View Comments and Join the Discussion!